European Off-Patent Industry Decries Price Cuts And Clawbacks
Medicines for Europe Calls For Pricing And Reimbursement Reform
A Medicines for Europe report on policies affecting the off-patent industry across 22 European countries aims to demonstrate the urgent need for pricing and reimbursement and procurement reforms.
You may also be interested in...
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
An average price rise of over 1,400% was seen for alendronate 70mg tablets in the UK last month, as average prices for a host of other generics more than doubled.
Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.